Enzymatic Lung Biocide Generation for Antibiotic Resistance

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current methods for treating respiratory infections, such as pneumonia, are ineffective against antibiotic-resistant bacteria and do not provide a means to deliver enzymatic activity directly to the respiratory tract to combat infection and inflammation.

Innovation Solution

A therapeutic composition comprising an oxidoreductase enzyme that produces hydrogen peroxide and a peroxidase enzyme, along with a salt that reacts with hydrogen peroxide to form a biocide, is delivered to the lungs using an aqueous or non-aqueous medium, allowing for the generation of a therapeutically effective concentration of biocide within the respiratory tract.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antibiotics are used to treat respiratory infections, then bacterial infections can be controlled, but antibiotic-resistant bacteria emerge and render treatments ineffective

Engineering Contradiction:
Improveeffectiveness of treatmentVSAvoidantibiotic resistance
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent converts hydrogen peroxide, which can be harmful at high concentrations, into a beneficial therapeutic agent by using peroxidase enzymes to generate it in situ within the lungs. The enzyme system transforms this potentially damaging substance into a controlled biocidal agent that kills bacteria without contributing to antibiotic resistance, effectively converting a harmful factor into a therapeutic benefit.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent introduces peroxidase enzymes as intermediary agents that facilitate the generation of hydrogen peroxide from oxygen and hydrogen donors within the lung tissue. These enzymes act as mediators between available substrates and the desired biocidal effect, enabling localized production of therapeutic concentrations of hydrogen peroxide without requiring direct administration of the peroxide itself.

Inventive Principle:
Principle #24Intermediary (Mediator)

2Ease of operation

If enzymatic treatment is delivered systemically, then the enzymes can reach the respiratory tract, but the complexity of delivery and achieving effective concentrations increases

Engineering Contradiction:
Improvedelivery methodVSAvoiddelivery system complexity
Core Design Contradiction:
Ease of operationVSDevice complexity

Solution Approach 1:

The patent segments the enzymatic treatment into multiple components: peroxidase enzymes, hydrogen donors (substrates), and oxygen sources. These segmented components can be administered separately or in combination, allowing flexibility in delivery routes (inhalation, injection, topical application) and simplifying the overall delivery system while ensuring the enzymes reach the respiratory tract at effective concentrations.

Inventive Principle:
Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition effectively treats lung diseases and conditions by generating biocides within the lungs, addressing antibiotic-resistant infections and inflammation, and can be administered via a ventilator, vaporizer, or nebulizer for targeted delivery.

Implementation Method 1

an oxidoreductase enzyme that produces hydrogen peroxide by catalyzing the oxidation of a substrate

Methodology Applied
Scientific EffectOxidation: Oxidation

Implementation Method 2

a peroxidase enzyme that catalyzes a reaction between hydrogen peroxide and a salt that acts as an oxygen acceptor and is capable of reacting with hydrogen peroxide to form a biocide

Methodology Applied
Scientific EffectPeroxidase reaction: Catalysis

Data Source

PatentUS10245303B2Compositions and methods for enzymatic treatment of lung disorders
Publication Date: 2019.04.02 LACLEDE INC

AI summary

A therapeutic composition for the treatment of lung diseases or disorders and diseases or disorders of the airway passages including pneumonia, acute respiratory failure, and acute respiratory distress syndrome is based on the generation of a biocidal anion by an enzymatic reaction catalyzed by a peroxidase. The peroxide utilized by the peroxidase enzyme can be endogenous or can be generalized by the action of an oxidase enzyme on a suitable substrate.